SCHEMBL2827577

SCHEMBL2827577

CC=Cc1c[nH]c(=O)nc1N

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.31
NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511404 1.00 KDM5A (0.31) KDM5ANOS2
SCHEMBL11153548 0.81
SCHEMBL532662 0.81 DPYD (0.31)
SCHEMBL932306 0.81
SCHEMBL8997737 0.81 DPYD (0.31)
SCHEMBL7599500 0.79 TDO2 (0.39)
SCHEMBL1179741 0.79 CYP2A6 (0.34)
SCHEMBL16784516 0.77 MAP3K7 (0.40)
SCHEMBL3823196 0.77 DPYD (0.42)
SCHEMBL7599692 0.76 TLR8 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 US claimed
US-20250170161-A1 INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF RISEN (SHANGHAI) MEDICINAL TECHNOLOGY CO., LTD. (CN) 2025-05-29 US disclosed
WO-2025082058-A1 DSRNA THAT INHIBITS EXPRESSION OF LPA GENE AND USE THEREOF 润佳(上海)医药技术有限公司 2025-04-24 WO disclosed
WO-2025082057-A1 INHIBITOR FOR INHIBITING EXPRESSION OF INHIBIN BETA E GENE AND USE THEREOF 润佳(上海)医药技术有限公司 2025-04-24 WO disclosed
EP-2915815-B1 NEW MODIFIED NUCLEIC ACID TAKEDA PHARMACEUTICALS CO (JP) 2018-01-17 EP disclosed
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 US disclosed
US-20160016983-A1 New Modified Nucleic Acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-21 US disclosed
EP-2915815-A1 NEW MODIFIED NUCLEIC ACID Takeda Pharmaceutical Company Limited (JP) 2015-09-09 EP disclosed
US-20100290992-A1 NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS ROCHE DIAGNOSTICS GMBH (DE) 2010-11-18 US disclosed
EP-1874790-B1 NEW S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES RWTH AACHEN (DE) 2010-08-18 EP disclosed
WO-2006108678-A2 NEW S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES RWTH AACHEN (DE) 2006-10-19 WO disclosed
EP-1712557-A1 New s-adenosyl-L-methionine analogues with extended activated groups for transfer by methyltransferases RWTH Aachen (DE) 2006-10-18 EP disclosed
EP-0135587-B2 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS SYNGENE INC (US) 2002-12-18 EP disclosed
US-5668266-A Synthesis of single-stranded labelled oligonucleotides of preselected sequence SYNGENE, INC. (US) 1997-09-16 US disclosed
US-5541313-A Single-stranded labelled oligonucleotides of preselected sequence MOLECULAR BIOSYSTEMS, INC. (US) 1996-07-30 US disclosed
US-4948882-A Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis SYNGENE, INC. (US) 1990-08-14 US disclosed
EP-0135587-B1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS SYNGENE, INC. (US) 1990-05-02 EP disclosed
EP-0135587-A4 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. MOLECULAR BIOSYSTEMS INC (US) 1986-04-02 EP disclosed
EP-0135587-A1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS. MOLECULAR BIOSYSTEMS INC (US) 1985-04-03 EP disclosed
WO-1984003285-A1 DEFINED SEQUENCE SINGLE STRAND OLIGONUCLEOTIDES INCORPORATING REPORTER GROUPS, PROCESS FOR THE CHEMICAL SYNTHESIS THEREOF, AND NUCLEOSIDES USEFUL IN SUCH SYNTHESIS MOLECULAR BIOSYSTEMS INC (US) 1984-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170161-A1 INHIBIN SUBUNIT BETA E INHIBITOR AND METHODS OF USE THEREOF INHA, IGF2BP1, IGF2BP2 KDM5A 3434/4885NOS2 3819/4885
US-20160016983-A1 New Modified Nucleic Acid RNGTT, RNASEH1, RNASE1 KDM5A 3059/4885NOS2 4616/4885
US-20100290992-A1 NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS POLM, IGF2BP1, POLRMT KDM5A 3126/4885NOS2 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.